Original Publication Date: 1 August, 2015
Publication / Source: International Journal of Endocrine Oncology
Authors: Yada Kanjanapan, Thiru Prasanna, Sumathy Perampalam & Desmond Yip
Adrenocortical carcinoma is a rare entity affecting 1–2 people per million. It has a relatively poor prognosis, with an overall 5-year survival of 20–45%. The reasons include a high risk of recurrence following resection and relatively poor response to cytotoxic treatment. The use of the adrenalytic mitotane as adjuvant therapy is supported by level III evidence from cohort studies.